Design, preparation and biological evaluation of new Rociletinib-inspired analogs as irreversible EGFR inhibitors to treat non-small-cell-lung cancer

Simple item page
dc.contributor.authorAdchata Konsue
dc.contributor.authorThomanai Lamtha
dc.contributor.authorDuangkamol Gleeson
dc.contributor.authorDonald J L Jones
dc.contributor.authorRobert G Britton
dc.contributor.authorJames D Pickering
dc.contributor.authorKiattawee Choowongkomon
dc.contributor.authorM Paul Gleeson
dc.date.accessioned2025-07-21T06:12:01Z
dc.date.issued2024-09-07
dc.identifier.doi10.1016/j.bmc.2024.117906
dc.identifier.urihttps://dspace.kmitl.ac.th/handle/123456789/13923
dc.subjectT790M
dc.subjectEGFR Inhibitors
dc.subject.classificationLung Cancer Treatments and Mutations
dc.titleDesign, preparation and biological evaluation of new Rociletinib-inspired analogs as irreversible EGFR inhibitors to treat non-small-cell-lung cancer
dc.typeArticle

Files

Collections

All